← Back to Search

NMDA Receptor Antagonist

Ketamine for Treatment-Resistant Depression

Phase 3
Recruiting
Led By Abraham Nunes, MD PhD MBA FRCPC
Research Sponsored by Abraham Nunes
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 14 days before the first infusion, 7 days before the first infusion, 1 day before the first infusion, day of the infusions, 24 hours, 7 days, 20 days after each infusion
Awards & highlights

Summary

This trial aims to find out which patients with TRD are most likely to benefit from a single low dose of IV ketamine to reduce symptoms quickly.

Who is the study for?
This trial is for adults with treatment-resistant depression (TRD) who have not responded to at least two different antidepressant medications and one augmentation agent. Participants must be fluent in English, able to understand the study, provide consent, and commit to using birth control if applicable. Exclusions include certain medical conditions like liver disease or recent heart attack, substance abuse issues, use of specific drugs like naltrexone, and previous ketamine therapy.Check my eligibility
What is being tested?
The trial tests whether a single low dose of IV ketamine can quickly relieve symptoms of TRD compared to an active placebo (Midazolam). It aims to identify predictors for who will benefit most from this treatment by observing responses at 24 hours and sustained effects up to two weeks after administration.See study design
What are the potential side effects?
Ketamine may cause side effects such as disorientation, dizziness, nausea, increased blood pressure and heart rate shortly after infusion. Long-term safety is unclear; hence the study's focus on short-term response.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~14 days before the first infusion, 7 days before the first infusion, 1 day before the first infusion, day of the infusions, 24 hours, 7 days, 20 days after each infusion
This trial's timeline: 3 weeks for screening, Varies for treatment, and 14 days before the first infusion, 7 days before the first infusion, 1 day before the first infusion, day of the infusions, 24 hours, 7 days, 20 days after each infusion for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Montgomery Åsberg Depression Rating Scale Score
Secondary outcome measures
Basic Language Morningness Scale
Dimensional Anhedonia Rating Scale
Epworth Sleepiness Scale
+5 more
Other outcome measures
Effect of treatment on mnemonic discrimination performance in depression
Measures of psychomotor behaviour to predict depressive severity
Migraine Severity Questionnaire

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: KetamineExperimental Treatment1 Intervention
Participants will be randomly assigned to receive Ketamine or Midazolam
Group II: MidazolamActive Control1 Intervention
Participants will receive either Ketamine or Midazolam based on what they initially received
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ketamine
2011
Completed Phase 4
~1120

Find a Location

Who is running the clinical trial?

Nova Scotia Health AuthorityOTHER
264 Previous Clinical Trials
85,876 Total Patients Enrolled
6 Trials studying Bipolar Disorder
30,531 Patients Enrolled for Bipolar Disorder
Abraham NunesLead Sponsor
Abraham Nunes, MD PhD MBA FRCPCPrincipal InvestigatorNova Scotia Health Authority

Media Library

Ketamine (NMDA Receptor Antagonist) Clinical Trial Eligibility Overview. Trial Name: NCT05625555 — Phase 3
Bipolar Disorder Research Study Groups: Ketamine, Midazolam
Bipolar Disorder Clinical Trial 2023: Ketamine Highlights & Side Effects. Trial Name: NCT05625555 — Phase 3
Ketamine (NMDA Receptor Antagonist) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05625555 — Phase 3
~18 spots leftby Jan 2025